Travere Therapeutics (TVTX) Retained Earnings (2011 - 2026)
Travere Therapeutics (TVTX) posted Retained Earnings of -$1.1 million for Q1 2026, up 99.93% on a QoQ basis from -$1.5 billion in Q4 2025, and down 100.07% year-over-year from $1.5 billion in Q1 2025.
Travere Therapeutics (TVTX) Retained Earnings (2011 - 2026) Analysis & Trends
Travere Therapeutics' Retained Earnings history runs 16 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- Quarterly Retained Earnings fell 100.07% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 million (down 100.07% YoY) and the FY2025 annual result came in at -$1.5 billion, down 1840791.25% from the prior year.
- Retained Earnings was -$1.1 million for Q1 2026 at Travere Therapeutics, up from -$1.5 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $1.5 billion in Q2 2025 and bottomed at -$1.5 billion in Q4 2025.
- A 5-year average of -$174764.7 and a median of -$1.1 million in 2026 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings soared 61572.33% — and 2025, when it plunged 1840791.25%.
- Travere Therapeutics' Retained Earnings stood at $1.1 billion in 2022, then tumbled by 206.19% to -$1.1 billion in 2023, then jumped by 99.99% to -$80000.0 in 2024, then plunged by 1840791.25% to -$1.5 billion in 2025, then surged by 99.93% to -$1.1 million in 2026.
- Business Quant data shows TVTX's Retained Earnings at -$1.1 million in Q1 2026, -$1.5 billion in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -1.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.06 Mn |
| Dec 31, 2025 | -1.47 Bn |
| Sep 30, 2025 | -1.05 Mn |
| Jun 30, 2025 | 1.53 Bn |
| Mar 31, 2025 | 1.52 Bn |
| Dec 31, 2024 | -80,000.00 |
| Sep 30, 2024 | 1.36 Bn |
| Jun 30, 2024 | -1.33 Bn |
| Mar 31, 2024 | 1.34 Bn |
| Dec 31, 2023 | -1.13 Bn |
| Sep 30, 2023 | -3.65 Mn |
| Jun 30, 2023 | -1.19 Bn |
| Mar 31, 2023 | -2.18 Mn |
| Dec 31, 2022 | 1.06 Bn |
| Sep 30, 2022 | 303,000.00 |
| Jun 30, 2022 | -878.74 Mn |
| Mar 31, 2022 | -811.71 Mn |
| Dec 31, 2021 | -765.97 Mn |
| Sep 30, 2021 | -714.39 Mn |
| Jun 30, 2021 | -641,000.00 |